Sexual health and erectile function in men with lung cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Kidney & urinary, Lungs & breathing, Mental health clinical trials.
This study looks at how lung cancer and its treatments affect men's sexual health, including erectile function and hormone levels. If you are a man with advanced lung cancer and are sexually active, researchers want to learn about your experiences and test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man with advanced or metastatic non-small cell lung cancer (NSCLC).
- You are ready to start an active cancer treatment.
- You are between 18 and 75 years old.
- You have been sexually active in the last 30 days before starting treatment.
- You are generally in good health (ECOG score 0-1) and can walk and take care of yourself.
- You are not taking certain medications that affect sexual function, like opiates, anxiety meds, beta blockers, or high-dose diuretics.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of hormone therapy (androgen deprivation) and an immunotherapy drug (anti-PD-1) for men with advanced lung cancer. It aims to see if this combination slows cancer growth better than standard treatments.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This trial is looking at how well a lung cancer treatment improves survival. It enrolls adults with confirmed lung cancer who can safely take the study medicines and have cancer that can be measured on scans.
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.